Current Colorectal Cancer Reports

, Volume 8, Issue 3, pp 170–176

Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

DOI: 10.1007/s11888-012-0134-5

Cite this article as:
Saltz, L.B. Curr Colorectal Cancer Rep (2012) 8: 170. doi:10.1007/s11888-012-0134-5


KRAS mutation has been demonstrated to be an important marker which can be utilized to identify a subset of patients who will not benefit from, and may, in fact, be harmed by, treatment with anti- EGFR agents. The presence of an exon 2 KRAS mutation tells us not to use an anti-EGFR monoclonal antibody. A KRAS wild type result tells us that the option of using an anti-EGFR monoclonal antibody does exist, however it does not compel the use of these antibodies in first-line regimens. How and when to utilize the anti-EGFR agents in the management of patients with KRAS wild type tumors is the subject of this manuscript.


Colorectal KRAS Wild type EGFR Cetuximab Panitumumab 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Weill Medical College of Cornell UniversityNew YorkUSA
  3. 3.New YorkUSA

Personalised recommendations